Guardant 360 Bundle(740Gene Liquid+740Gene Tissue)

What is the Guardant 360 Bundle test?

The Guardant 360 Bundle is a comprehensive genomic profiling test that analyses cancer-related genetic mutations using both liquid biopsy and tissue biopsy samples. The test evaluates approximately 740 genes associated with different types of cancers. It helps identify actionable mutations that may guide targeted cancer therapy and personalized treatment planning.

Why is the Guardant 360 Bundle test done?

• To detect cancer-related genetic mutations.
• To support personalized cancer treatment decisions.
• To identify targeted therapy options.
• To monitor tumor evolution and treatment resistance.
• To assist in advanced cancer management.

Who should get tested for the Guardant 360 Bundle test?

• Patients diagnosed with advanced or metastatic cancer.
• Individuals requiring comprehensive tumor genomic profiling.
• Cancer patients with treatment-resistant disease.
• Patients advised for precision oncology testing by oncologists.

More about the Guardant 360 Bundle test

Guardant 360 Bundle test combines liquid biopsy and tissue genomic analysis for broader mutation detection. Liquid biopsy uses a blood sample to detect circulating tumor DNA, while tissue analysis evaluates tumor-specific mutations directly from biopsy tissue.

Other/Similar names of the test

• Comprehensive Cancer Genomic Profiling
• Liquid Biopsy Cancer Test
• Guardant test
• Guardant 360 test